A number of other research analysts have also recently commented on VKTX. ValuEngine cut Viking Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday. William Blair reiterated an “outperform” rating on shares of Viking Therapeutics in a report on Friday, March 29th. HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Viking Therapeutics in a report on Thursday, April 11th. Svb Leerink upgraded Viking Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $10.00 to $21.00 in a report on Friday, March 29th. Finally, Maxim Group decreased their price objective on Viking Therapeutics from $28.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 14th. One equities research analyst has rated the stock with a sell rating, ten have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $22.54.
Shares of Viking Therapeutics stock opened at $8.46 on Friday. The company has a market cap of $584.87 million, a PE ratio of -21.15 and a beta of 2.57. Viking Therapeutics has a 1-year low of $4.05 and a 1-year high of $24.00.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in VKTX. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Viking Therapeutics during the fourth quarter worth $30,000. Lindbrook Capital LLC acquired a new position in Viking Therapeutics during the fourth quarter worth $36,000. Great West Life Assurance Co. Can acquired a new position in Viking Therapeutics during the fourth quarter worth $53,000. Meeder Asset Management Inc. lifted its stake in Viking Therapeutics by 63.5% during the fourth quarter. Meeder Asset Management Inc. now owns 7,309 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 2,839 shares in the last quarter. Finally, Nisa Investment Advisors LLC acquired a new position in Viking Therapeutics during the fourth quarter worth $60,000. Hedge funds and other institutional investors own 65.13% of the company’s stock.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.